Posts

US lawmakers intensify scrutiny of Chinese clinical trials, raising industry concerns over cost and disruption

on

The Endpoints 100: Biotech CEOs are feeling more upbeat about the road ahead

on

Arena BioWorks Shuts Down After Investors Withdraw Support for Bold Biotech Model

on

Are the Good Times in Biotech Back? – Insights from Post-Hoc Live’s 2025 Industry Sentiment

on

UK Proposes Raising Payment Scheme for Branded Medicines to Nearly 25% Amid Industry Pushback

on

Endpoints News Launches Industry Sentiment Survey, But No Evidence Yet of a New Biopharma Sentiment Index

on

Meeting on the Mesa 2025 Arrives Amid Mixed Signals for Cell and Gene Therapy Sector

on

Takeda to Cut 137 Staffers After Exiting Cell Therapy Research

on

Endpoints News to Announce 2025 'Endpoints 11' Biotechs to Watch Live in Boston

on

How Past Endpoints 11 Winners Fared During the 2025 Biotech Downturn

on

Endpoints 11: Biopharma’s most promising startups revealed live in Boston this September

on

Ignoring China's Biotech Industry Is No Longer an Option: Recent Developments and Implications

on

Biopharma Layoffs Continue to Surge in First Half of 2025

on

Exit Strategy: Biopharma Professionals Consider Opportunities Outside Industry and US

on

Sanofi Commits $20 Billion to US Expansion Amid Industry-Wide Investment Surge

on

AI Drug Discovery Firm Insitro Lays Off 22% of Workforce Amid Ongoing Biotech Market Turmoil

on

Biotech stocks plunge and industry figures left to wonder after Prasad's FDA appointment

on

Exclusive: Vertex drops AAV gene therapy research, tRNA therapy partnership

on

2 years after leaving PhRMA, AstraZeneca opts back in

on

Chinese CRO GemPharmatech expands in San Diego as industry weighs FDA's animal testing shift

on